UGT与CYP2C8交互作用对CYP2C8介导药物氧化及氯吡格雷、吉非贝齐所致药物相互作用的影响
本研究基于文献血浆数据与模拟,探讨UGT与CYP2C8在CYP2C8底物药物相互作用中的交互作用。发现吉非贝齐同时抑制UGT和CYP2C8,氯吡格雷仅抑制CYP2C8,且抑制由酰基葡萄糖苷酸介导。UGT-CYP2C8交互模型可准确预测DDI所致原药及代谢物血浆水平变化。
要点
- 吉非贝齐抑制UGT(50%)和CYP2C8(93%),氯吡格雷仅抑制CYP2C8(85%)。
- CYP2C8抑制为非竞争性,由酰基葡萄糖苷酸介导。
- 预测DDI需考虑CYP2C8和UGT对清除的分数贡献。
核心结论
- UGT介导的分布对CYP2C8底物代谢及氯吡格雷、吉非贝齐所致DDI具有关键作用。
- UGT-CYP2C8交互模型能准确预测DDI引起的原药及代谢物血浆水平变化和代谢物生成速率改变。
研究设计与样本
- 基于文献中未变化药物及其代谢物的血浆水平数据进行分析。
- 利用模拟评估DDI的酶抑制活性,并估算各DDI中未变化底物药物及其代谢物的血浆水平。
- 采用考虑CYP2C8和UGT对清除分数贡献、抑制药特异性抑制活性及药物向UGT分布的功能关系。
主要发现
- 吉非贝齐对UGT和CYP2C8均有抑制作用,氯吡格雷(其代谢物Clop-COOH)仅靶向CYP2C8。
- 氯吡格雷和吉非贝齐对CYP2C8的抑制均为非竞争性机制,由其酰基葡萄糖苷酸驱动。
- 氯吡格雷和吉非贝齐的抑制活性分别占85%(pAi,CYP2C8 = 7)和93%(pAi,CYP2C8 = 15)。
- 吉非贝齐对UGT的抑制相对温和(50%,pAi,UGT(d) = 2),通过非特异性竞争过程作用于药物向UGT的分布。
- 在DDI预测中考虑CYP2C8和UGT对底物药物清除的分数贡献(fm,CYP2C8; fm,UGT)至关重要。
关键数值与推荐
- 氯吡格雷对CYP2C8抑制活性占85%(pAi,CYP2C8 = 7)。
- 吉非贝齐对CYP2C8抑制活性占93%(pAi,CYP2C8 = 15)。
- 吉非贝齐对UGT抑制活性占50%(pAi,UGT(d) = 2)。
临床怎么用
- 临床评估CYP2C8底物药物与氯吡格雷或吉非贝齐的DDI时,应同时考虑UGT介导的分布和CYP2C8氧化。
- 使用UGT-CYP2C8交互模型预测DDI对原药和代谢物血浆水平的影响。
- 对于OATP1B1底物药物,DDI预测中无需额外考虑肝脏摄取转运体作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Early investigations into drug-drug interactions (DDIs) involving cytochrome P450 2C8 (CYP2C8) have highlighted the complexity of interactions between CYP2C8 substrate drugs, including montelukast, desloratadine, pioglitazone, repaglinide, and cerivastatin (the latter two being OATP1B1 substrates), and standardized CYP2C8 inhibitors such as clopidogrel (Clop) and gemfibrozil (Gem). These interactions have proven challenging to predict based solely on simple CYP inhibition. A hypothesis has emerged suggesting that these substrate drugs first distribute to UDP-glucuronosyltransferase (UGT) before undergoing oxidation by CYP2C8, resulting in bidirectional elimination. The process of drug distribution to UGT is believed to significantly impact these DDIs. This study aims to explore the intricate interplay between UGT and CYP2C8 in the context of DDIs involving CYP2C8 substrates affected by Clop and Gem. METHODS: Plasma-level data for the unchanged drug and its metabolite, drawn from the respective literature, formed the basis of our analysis. We evaluated the enzymatic inhibitory activities of DDIs and utilized simulations to estimate plasma levels of the unchanged victim drug and its metabolite in each DDI. This was accomplished by employing a functional relationship that considered the fractional contributions of CYP2C8 and UGT to clearance, perpetrator-specific inhibitory activities against CYP2C8, and drug distribution to UGT. RESULTS: Our findings emphasize the pivotal role of UGT-mediated distribution in the context of CYP2C8 substrate metabolism, particularly in the complex DDIs induced by Clop and Gem. In these DDIs, Gem exerts inhibitory effects on both UGT and CYP2C8, whereas Clop (specifically its metabolite, Clop-COOH) solely targets CYP2C8. Importantly, the inhibition of CYP2C8 by both Clop and Gem is achieved through a non-competitive mechanism, driven by the actions of their acyl-glucuronides. Clop and Gem exhibit inhibition activities accounting for 85% (pAi,CYP2C8 = 7) and 93% (pAi,CYP2C8 = 15), respectively. In contrast, Gem's inhibition of UGT is relatively modest (50%, pAi,UGT(d) = 2), and it operates through a non-specific, competitive process in drug distribution to UGT. Within this context, our UGT-CYP2C8 interplay model offers an accurate means of predicting the alterations resulting from DDIs, encompassing changes in plasma levels of the unchanged drug and its metabolites, as well as shifts in metabolite formation rates. Our analysis highlights the critical importance of considering the fractional contributions of CYP2C8 and UGT to the victim drug's clearance (fm,CYP2C8; fm,UGT) in DDI prediction. Furthermore, our examination of DDIs involving OATP1B1 substrate drugs underscores that accounting for the hepatic uptake transporters' role in the liver is superfluous in DDI prediction. CONCLUSION: These findings substantially enhance our comprehension of CYP2C8-mediated oxidation and DDIs, holding crucial implications for drug development and the planning of clinical trials involving these inhibitors.
引用
- Iga K, Kiriyama A. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil. Clin Pharmacokinet. 2023. PMID: 37921907. doi:10.1007/s40262-023-01322-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。